Evidence map›Paper›PMID 41198762›Full record

ArticleScientific reports2025

Development and validation of a prognostic nomogram for survival in patients with brain metastases from colorectal cancer.

Jun Imaizumi, Dai Shida, Narikazu Boku, Hiroshi Igaki, Yasuji Miyakita, Issei Kitabayashi, Yoshitaka Narita, Jun Itami, Atsuo Takashima, Yukihide Kanemitsu

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jun ImaizumiDepartment of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.
Dai ShidaDivision of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo, 1088639, Japan. dshida@g.ecc.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-3294-1924
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo, 1088639, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.
Yasuji MiyakitaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.
Issei KitabayashiCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 1138421, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.
Jun ItamiDepartment of Radiation Therapy, Shin-Matsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo-Shi, Chiba, 270-0034, Japan.
Atsuo TakashimaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 1040045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases from colorectal cancer are rare but carry a dismal prognosis. This study aimed to develop and externally validate a prognostic model for individualized survival prediction in affected patients. The model was constructed using a training cohort of 112 patients diagnosed with brain metastases after initial colorectal cancer treatment at our institution between 1985 and 2017, and validated in an external cohort of 114 patients referred for brain metastasis treatment between 1987 and 2017. A nomogram was developed incorporating five variables: age, performance status assessed by the Karnofsky Performance Status scale, number of brain metastases, maximum size of brain lesions, and number of prior systemic chemotherapy regimens. In the training cohort, the median survival was 6.6 months, with 1-year and 3-year survival rates of 29.0% and 7.2%. Poorer performance status, multiple metastases, and higher number of chemotherapy regimens were associated with worse prognosis. In the validation cohort, median survival was 5.8 months, with 1-year and 3-year survival rates of 27.0% and 8.4%. Harrell's concordance index was 0.70 for internal validation and 0.63 for external validation. This model may provide a clinically useful tool for individualized survival estimation in patients with brain metastases from colorectal cancer.

Indexed as

Brain NeoplasmsColorectal NeoplasmsNomogramsAdultAgedAged, 80 and overFemaleHumansKarnofsky Performance StatusMaleMiddle AgedPrognosisSurvival RateBrain metastasesColorectal cancerKarnofsky performance statusNomogramPrognosis

Identifiers

PMID41198762
PMCPMC12592325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.